ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.15
1.17%
Dow Jones
39,908.00
0.88%
US Dollar vs MXN
16.7253
0.25%
Brent Oil
82.22
-0.53%
Bitcoin
66,169.48
-0.14%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Stoke Therapeutics Inc (STOK)

  7. Stoke Therapeutics Inc (STOK) Noticias

STOK Stoke Therapeutics Inc

14.13
0.00 (0.00%)
Pre Mercado
Última actualización: 03:09:55
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Stoke Therapeutics Inc STOK NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 14.13 03:09:55
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
14.13
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
06/5/202415:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202406:05EDGAR2Form 8-K - Current report
06/5/202406:00BWStoke Therapeutics Reports First Quarter Financial Results..
29/4/202407:00BWStoke Therapeutics Appoints Thomas Leggett as Chief..
17/4/202407:00BWStoke Therapeutics Appoints Jason Hoitt as Chief Commercial..
04/4/202415:30BWStoke Therapeutics to Present at the 23rd Annual Needham..
27/3/202422:40BWStoke Therapeutics Announces Pricing of Upsized $125 Million..
26/3/202415:07BWStoke Therapeutics Announces Proposed Public Offering
25/3/202415:01BWStoke Therapeutics Announces Landmark New Data That Support..
05/3/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202415:28EDGAR2Form 144 - Report of proposed sale of securities
26/2/202409:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
26/2/202409:36EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202408:20EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202415:49EDGAR2Form 144 - Report of proposed sale of securities
17/1/202415:30BWStoke Therapeutics Announces Inducement Grants Under Nasdaq..
08/1/202407:09EDGAR2Form 8-K - Current report
08/1/202407:00BWStoke Therapeutics Highlights Strategic Priorities and..
04/1/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:30BWStoke Therapeutics to Present at the 42nd Annual J.P. Morgan..
02/1/202415:29EDGAR2Form 144 - Report of proposed sale of securities
14/12/202315:05EDGAR2Form 8-K - Current report
05/12/202315:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202315:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202315:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202315:08EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
01/12/202308:04EDGAR2Form 8-K - Current report
01/12/202308:00BWStoke Therapeutics Presents Data From Multiple Studies of..
21/11/202307:00BWStoke Therapeutics to Present Data from the Company’s Dravet..
17/11/202315:37EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
09/11/202315:28EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
07/11/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:05EDGAR2Form 8-K - Current report
07/11/202306:00BWStoke Therapeutics Reports Third Quarter Financial Results..
06/11/202315:55EDGAR2Form SC 13G - Statement of acquisition of beneficial..
02/11/202308:01EDGAR2Form SC TO-I - Tender offer statement by Issuer
26/10/202316:00EDGAR2Form 8-K - Current report
17/10/202315:30BWStoke Therapeutics Announces Inducement Grants Under Nasdaq..
28/9/202315:05EDGAR2Form DEF 14A - Other definitive proxy statements
21/9/202307:00BWStoke Therapeutics to Participate in the 2023 Cantor Global..
20/9/202315:37EDGAR2Form 8-K - Current report
20/9/202315:30BWStoke Therapeutics Appoints Ian Smith to its Board of..
18/9/202315:05EDGAR2Form PRE 14A - Other preliminary proxy statements
05/9/202306:00BWStoke Therapeutics Presents Data Related to the Ongoing..
07/8/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202306:05EDGAR2Form 8-K - Current report
07/8/202306:00BWStoke Therapeutics Reports Second Quarter Financial Results..
02/8/202307:00BWStoke Therapeutics to Present at the Canaccord Genuity 43rd..
25/7/202306:05EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
STOK
Stoke Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados